دورية أكاديمية
أعرض في EDS

Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee.

التفاصيل البيبلوغرافية
العنوان: Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee.
المؤلفون: John TD; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA., Maron G; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Abraham A; Center for Cancer and Immunology Research, CETI, Children's National Hospital, Washington, District of Columbia, USA., Bertaina A; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA., Bhoopalan SV; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Bidgoli A; Division of Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Blood and Cancer Disorders Center, Emory University, Atlanta, Georgia, USA., Bonfim C; Pediatric Blood and Marrow Transplantation Division and Pelé Pequeno Príncipe Research Institute, Hospital Pequeno Príncipe, Curitiba, Brazil., Coleman Z; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., DeZern A; Bone Marrow Failure and MDS Program, John Hopkins Medicine, Baltimore, Maryland, USA., Li J; Graduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia., Louis C; Zentalis Pharmaceuticals, New York, New York, USA., Oved J; Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Pavel-Dinu M; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA., Purtill D; Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia., Ruggeri A; IRCCS Ospedale San Raffaele, Segrate, Milan, Italy., Russell A; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Wynn R; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Boelens JJ; Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Prockop S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Electronic address: akshay.sharma@stjude.org.
المصدر: Cytotherapy [Cytotherapy] 2024 Jul; Vol. 26 (7), pp. 660-671. Date of Electronic Publication: 2024 Feb 20.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE
أسماء مطبوعة: Publication: 2013- : London : Elsevier
Original Publication: Oxford, England : ISIS Medical Media, c1999-
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/methods , Hematopoietic Stem Cell Transplantation*/adverse effects , Genetic Therapy*/methods, Humans ; Hematopoietic Stem Cells/cytology ; Cell- and Tissue-Based Therapy/methods ; Infections/therapy ; Infections/etiology
مستخلص: There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.
(Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
References: N Engl J Med. 2022 Feb 17;386(7):617-628. (PMID: 34898139)
Nat Med. 2022 Jan;28(1):81-88. (PMID: 35075288)
Clin Infect Dis. 2020 Jun 24;71(1):226-236. (PMID: 31676904)
Best Pract Res Clin Haematol. 2022 Sep;35(3):101399. (PMID: 36494150)
Pediatr Blood Cancer. 2016 May;63(5):908-13. (PMID: 26757445)
Bone Marrow Transplant. 2006 Jun;37(12):1119-28. (PMID: 16699530)
Int J Mol Sci. 2020 Apr 23;21(8):. (PMID: 32340185)
Nat Rev Clin Oncol. 2022 Aug;19(8):515-533. (PMID: 35614230)
Nat Med. 2022 Jan;28(1):71-80. (PMID: 35075289)
Bone Marrow Transplant. 1997 Jul;20(1):33-8. (PMID: 9232253)
J Pediatric Infect Dis Soc. 2021 Sep 23;10(8):864-871. (PMID: 34173659)
Front Pediatr. 2020 Aug 21;8:454. (PMID: 32974239)
Blood. 2009 Aug 6;114(6):1174-85. (PMID: 19474450)
Cancer Chemother Pharmacol. 2008 Oct;62(5):821-30. (PMID: 18246351)
N Engl J Med. 2022 Dec 22;387(25):2344-2355. (PMID: 36546626)
Front Immunol. 2020 Nov 27;11:608653. (PMID: 33329605)
Transplant Cell Ther. 2022 Dec;28(12):795-801. (PMID: 36058548)
Biol Blood Marrow Transplant. 2018 May;24(5):909-913. (PMID: 29360515)
Bone Marrow Transplant. 2021 Nov;56(11):2797-2803. (PMID: 34274957)
HIV Med. 2000 Mar;1(2):107-15. (PMID: 11737333)
Bone Marrow Transplant. 2009 Oct;44(8):453-5. (PMID: 19861977)
Front Immunol. 2021 Feb 25;12:648951. (PMID: 33717203)
Cancer Treat Rev. 2020 Jan;82:101929. (PMID: 31770695)
Blood. 2014 Jul 17;124(3):334-43. (PMID: 24914138)
Eur J Med Chem. 2022 Aug 5;238:114494. (PMID: 35665692)
J Clin Oncol. 2020 Sep 20;38(27):3205-3216. (PMID: 32459599)
Blood. 2016 Jun 9;127(23):2824-32. (PMID: 27048212)
Expert Rev Anticancer Ther. 2007 Jul;7(7):945-57. (PMID: 17627453)
Front Immunol. 2022 Sep 26;13:960749. (PMID: 36225916)
Hum Vaccin Immunother. 2015;11(12):2852-63. (PMID: 26291740)
Lancet. 2022 Jan 22;399(10322):372-383. (PMID: 35065785)
N Engl J Med. 2021 Jan 21;384(3):252-260. (PMID: 33283989)
Exp Hematol. 1985 Dec;13(11):1127-32. (PMID: 2933271)
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):748-758. (PMID: 30343510)
Blood. 2017 Mar 16;129(11):1548-1556. (PMID: 27965196)
Biol Blood Marrow Transplant. 2018 Jul;24(7):1313-1321. (PMID: 29653206)
Crit Rev Immunol. 2016;36(2):179-191. (PMID: 27910767)
J Clin Med. 2022 Feb 09;11(4):. (PMID: 35207178)
Curr Opin Hematol. 2012 Jan;19(1):44-51. (PMID: 22080845)
N Engl J Med. 2019 Apr 18;380(16):1525-1534. (PMID: 30995372)
N Engl J Med. 2021 Jan 21;384(3):205-215. (PMID: 33283990)
Br J Haematol. 2000 Jan;108(1):105-15. (PMID: 10651733)
Biol Blood Marrow Transplant. 2009 Dec;15(12):1538-42. (PMID: 19896077)
Expert Opin Biol Ther. 2022 Sep;22(9):1151-1162. (PMID: 36107226)
Clin Vaccine Immunol. 2014 Jul;21(7):982-8. (PMID: 24807051)
Br J Haematol. 2014 Jul;166(2):165-76. (PMID: 24862308)
Lancet Haematol. 2016 Nov;3(11):e526-e536. (PMID: 27746112)
Transplant Cell Ther. 2021 Apr;27(4):317-326. (PMID: 33836875)
Exp Hematol. 1999 Mar;27(3):561-8. (PMID: 10089920)
Curr Treat Options Neurol. 2019 Nov 25;21(12):61. (PMID: 31768791)
Mol Ther Methods Clin Dev. 2019 Oct 31;16:42-49. (PMID: 31763350)
Clin Infect Dis. 2020 Dec 3;71(9):2365-2374. (PMID: 32076709)
Paediatr Drugs. 2023 Mar;25(2):225-232. (PMID: 36572834)
Nat Commun. 2019 Feb 6;10(1):617. (PMID: 30728354)
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):328-335. (PMID: 33275684)
N Engl J Med. 2021 Nov 18;385(21):1929-1940. (PMID: 34788506)
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. (PMID: 28478586)
Biol Blood Marrow Transplant. 2009 May;15(5):523-36. (PMID: 19361744)
Nat Med. 2019 Sep;25(9):1396-1401. (PMID: 31501599)
Best Pract Res Clin Haematol. 2011 Sep;24(3):381-91. (PMID: 21925091)
Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):40-9. (PMID: 22252923)
N Engl J Med. 2021 May 27;384(21):2002-2013. (PMID: 33974366)
Ann Hematol. 2013 Apr;92(4):433-42. (PMID: 23412562)
Mayo Clin Proc. 2020 Apr;95(4):823-824. (PMID: 32247354)
N Engl J Med. 1983 Dec 1;309(22):1347-53. (PMID: 6355849)
N Engl J Med. 2017 Oct 26;377(17):1630-1638. (PMID: 28976817)
معلومات مُعتمدة: K99 DK134844 United States DK NIDDK NIH HHS; P30 CA021765 United States CA NCI NIH HHS; U01 HL163983 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: genetically modified hematopoietic stem cell therapies; immune reconstitution; prophylaxis; vaccination
تواريخ الأحداث: Date Created: 20240314 Date Completed: 20240628 Latest Revision: 20240701
رمز التحديث: 20240702
مُعرف محوري في PubMed: PMC11213676
DOI: 10.1016/j.jcyt.2024.02.005
PMID: 38483362
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-2566
DOI:10.1016/j.jcyt.2024.02.005